Abstract
Potent and selective antagonists of the vitronectin receptor αVβ3 (for example, 1) were obtained by incorporation of a central purine scaffold into RGD peptidomimetics. The ease of derivatization of the purine building block holds promise for many future uses of this scaffold in peptidomimetic chemistry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
